Business
Decision Diagnostics Conveys Opportunities and Potential Following Landmark Circuit Court Ruling Against Diabetes Testing Division of Johnson & Johnson
Decision Diagnostics Conveys Opportunities and Potential Following Landmark Circuit Court Ruling Against Diabetes Testing Division of Johnson & Johnson.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"\n \n \n Decision Diagnostics Conveys Opportunities and Potential Following Landmark Circuit Court Ruling Against Diabetes Testing Division of Johnson & Johnson\n \n \nDecision Diagnostics Conveys Opportunities and Potential Following Landmark Circuit Court Ruling Against Diabetes Testing Division of Johnson & Johnson\n\nFederal Circuit Court's Rule 36 Affirmation Positions DECN to Achieve Significant Market Penetration\n\n \n LOS ANGELES, CA--(Marketwired - Feb 9, 2016) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip™ 50 and the GenUltimate™ glucose test strip, both designed to work with the market leading Johnson & Johnson's (\"J&J\") LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure™ glucose test strip targeted to the developing world markets, today relays a summary of the arguably illegitimate J&J/Lifescan lawsuit impact on DECN business activity, its current status and future expectations. \n Corporate annual revenue generation approximated $15+ million from 2009-2012 from existing business activities, prior to the comprehensive 2012-2013 Medicare reimbursement reductions for at-home testing supplies. In 2012 the company assumed total program management of the Genstrip blood glucose test strip; including all regulatory activity directed towards FDA 510k market clearance. Concurrent to this transition, and prior to regulatory approval and Genstrip product introduction, J&J/Lifescan commenced its campaign of litigation, threats and intimidation to prevent the introduction of Genstrip to the diabetic patient population. They collectively filed patent infringement and trademark infringement lawsuits.\n The FDA 510k market clearance in November, 2012, activated an intensive product launch and initiated an order wave that deluged manufacturing and overwhelmed capacity. Agreements were quickly executed with mass merchandisers, drug chains and grocery retailers. However, internal expectations for meteoric product growth and rapid revenue escalation were abruptly interrupted by lower court judges, persuaded by J&J/Lifescan assertions of false health risks and their own financial impairment, to enter two preliminary injun...